Recent advances in pulmonary fibrosis: Implications for scleroderma

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 683-689

  Homer, Robert J ^a   Herzog, Erica L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

epithelial injury; epithelial mesenchymal transition; fibrocytes; M2 macrophages; Wnt pathways

Indexed keywords

AMYLOID P COMPONENT; BETA CATENIN; CD4 ANTIGEN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TENSIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; WNT PROTEIN; WNT1 PROTEIN;

APOPTOSIS; CELL AGING; CELL DAMAGE; EFFEROCYTOSIS; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; IMMUNE RESPONSE; LUNG ALVEOLUS CELL TYPE 2; LUNG FIBROSIS; LUNG PARENCHYMA; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; MOLECULAR DYNAMICS; MORTALITY; MYOFIBROBLAST; NONHUMAN; OCULAR ALBINISM; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SCAR; SCLERODERMA; SENESCENCE; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; THERAPY EFFECT;

ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION; RESPIRATORY MUCOSA; SCLERODERMA, SYSTEMIC;

EID: 77958038345     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833ddcc9     Document Type: Review

References (48)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944.
2. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144 (3 Pt 1):706-713.
3. Au u, Khanna D, Clements PJ, et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessonsfrom clinical trials. Curr Rheumatol Rep 2009; 11: 111-119.
4. Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung transplantation: a single center experience. Eur Respir J 2010. [Epub ahead ofprint]
5. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and reg-ulation. Mucosal Immunol 2009; 2:103-121.
6. Mendez M,Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J RespirCritCare Med 2010; 181:254-263.
7. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61:105-119.
8. Mahavadi P, Korfei M, Henneke I, et al. Epithelial stress and apoptosis underlie Hermansky-Pudlak syndrome associated interstitial pneumonia. Am J RespirCrit Care Med 2010. [Epub ahead of print]
9. Konigshoff M, BalsaraN, Pfaff EM, et al. Functional Wnt signaling is increasedin idiopathic pulmonary fibrosis. PLoS One 2008; 3:e2142.
10. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans withidiopathic pulmonary fibrosis. J Clin Invest 2009; 119:772-787.
11. Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibroticphenotype. Lab Invest 2010; 90:812-823.
12. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects onmacrophages. PLoS One 2010; 5:e9683.
13. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451-483.
14. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apop-tosis. J Exp Med 2009; 206:1149-1166.
15. Hartl D, HeCH, Koller B, et al. Acidic mammalian chitinase regulates epithelial cell apoptosis via a chitinolytic-independent mechanism. J Immunol 2009;182:5098-5106.
16. Jiang D, Liang J, CampanellaGS, et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J ClinInvest 2010; 120:2049-2057.
17. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003; 171:5537-5546.
18. van Lieshout AW, Vonk MC, Bredie SJ, et al. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4agonists in systemic sclerosis that is possibly implicated in CCL18 secretion.Scand J Rheumatol 2009; 38:282-290.
19. Ishii M, Wen H, Corsa CA, et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009; 114:3244-3254.
20. Medeiros AI, Serezani CH, Lee SP, Peters-Golden M. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. J Exp Med 2009; 206:61-68.
21. Castano AP, Lin SL, SurowyT, et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci TranslMed 2009; 1:5ra13.
22. Wang L, Scabilloni JF, Antonini JM, et al. Induction of secondary apoptosis,inflammation, and lung fibrosis after intratracheal instillation of apoptotic cellsin rats. Am J Physiol Lung Cell Mol Physiol 2006; 290:L695-L702.
23. Broen J, Gourh P, Rueda B, et al. The FAS \-670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes. Arthritis Rheum2009; 60:3815-3820.
24. Gasse P, Riteau N, Charron S, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir CritCare Med 2009; 179:903-913.
25. Kim KK, Wei Y, Szekeres C, et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation andpulmonary fibrosis. J Clin Invest 2009; 119:213-224.
26. Kim Y, Kugler MC, Wei Y, et al. Integrin alpha3beta1-dependent beta-catenin phosphorylation links epithelial Smad signaling to cell contacts. J Cell Biol2009; 184:309-322.
27. Pozharskaya V, Torres-Gonzalez E, Rojas M, et al. Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis. PLoSOne 2009;4:e7559.
28. Jayachandran A, Konigshoff M, Yu H, et al. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. Thorax 2009; 64:1053-1061.
29. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol 2010; 38:548-556.
30. Andersson-Sjoland A, Erjefalt JS, Bjermer L, et al. Fibrocytes are associated with vascular and parenchymal remodelling in patients with obliterativebronchiolitis. Respir Res 2009; 10:103.
31. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009;41:1708-1718.
32. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med2009; 179:588-594.
33. Pilling D, Fan T, Huang D, et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts.PLoS One 2009; 4:e7475.
34. + monocytes into fibrocytes. Proc Natl Acad Sci USA2009; 106:17892-17897.
35. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317-1326.
36. Tarhan F, Vural F, Kosova B, et al. Telomerase activity in connective tissue diseases: elevated in rheumatoid arthritis, but markedly decreased in systemic sclerosis. Rheumatol Int 2008; 28:579-583.
37. Mathew R, Jia W, Sharma A, et al. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J 2010. [Epub ahead of print]
38. Xia H, Khalil W, Kahm J, et al. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010; 176:2626-2637.
39. Tourkina E, Richard M, Oates J, et al. Caveolin-1 regulates leucocyte beha-viour in fibrotic lung disease. Ann Rheum Dis 2010; 69:1220-1226.
40. Bu S, Asano Y, Bujor A, et al. Dihydrosphingosine-1 phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of PTEN levels.Arthritis Rheum 2010; 62:2117-2126.
41. Xu J, Gonzalez ET, Iyer SS, et al. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derivedcells can alter the outcome of lung injury in aged mice. J Gerontol A Biol SciMed Sci 2009; 64:731-739.
42. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology(Oxford) 2010; 49:271-280.
43. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator ofpulmonary fibrotic activity in idiopathic interstitial pneumonias and systemicsclerosis. Arthritis Rheum 2007; 56:1685-1693.
44. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J RespirCrit Care Med 2009; 179:717-723.
45. Luzina IG, Todd NW, Nacu N, et al. Regulation of pulmonary inflamma-tion and fibrosis through expression of integrins alphaVbeta3 andalphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum 2009; 60:1530-1539.
46. + regulatory T cells in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2009; 179:1121-1130.
47. Slobodin G, Ahmad MS, Rosner I, et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlateswith disease activity and severity. Cell Immunol 2010; 261:77-80.
48. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathicpulmonary fibrosis. PLoS One 2010; 5:e8959.